BridgeMD
New treatment option for Atopic Dermatitis (AD)
Official title Effect of an Emollient Cream Containing a Milk Bioactive Peptide on Clinical Signs, Pruritus and Bacterial Colonization of Mild Atopic Dermatitis Skin Lesions in Pediatric Population
ClinicalTrials.gov ID: NCT07259343
What this study is testing
- What it's testing
- The goal of this clinical trial is to evaluate the protective effect of glycomacropeptide on the clinical signs and symptoms of atopic dermatitis in children aged 2 to 12 years, and to determine if topical administration of glycomacropeptide is associated with a lower colonization by Staphylococcus species on the skin. The main questions that it aims to answer are: Does glycomacropeptide reduce the signs and symptoms related to atopic dermatitis in the pediatric population?
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 2 to 12
You may be able to join if
- Children aged between 2 and 12 years.
- Clinical diagnosis of atopic dermatitis according to Hanifin and Rajka criteria.
- Mild atopic dermatitis with SCORAD \<25 points.
- Written informed consent signed by parents or legal guardian.
You likely can't join if
- Age younger than 2 years or older than 12 years.
- Moderate to severe atopic dermatitis (SCORAD \>25 points).
- Presence of other dermatoses in addition to atopic dermatitis.
- Background of hypersensitivity or anaphylaxis to any components of the vehicle cream.
- Allergy or hypersensitivity to glycomacropeptide.
- Inability to attend follow-up medical consultations or to adhere to the treatment schedule.
See the full eligibility criteria
- Children aged between 2 and 12 years.
- Clinical diagnosis of atopic dermatitis according to Hanifin and Rajka criteria.
- Mild atopic dermatitis with SCORAD \<25 points.
- Written informed consent signed by parents or legal guardian.
- Age younger than 2 years or older than 12 years.
- Moderate to severe atopic dermatitis (SCORAD \>25 points).
- Presence of other dermatoses in addition to atopic dermatitis.
- Background of hypersensitivity or anaphylaxis to any components of the vehicle cream.
- Allergy or hypersensitivity to glycomacropeptide.
- Inability to attend follow-up medical consultations or to adhere to the treatment schedule.
- Any clinical reason determined by the clinical investigator that makes the child unsuitable for the study.
The study team makes the final eligibility decision.
Where it's taking place
- Aguascalientes, Aguascalientes, Mexico
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 2 years to 12 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Aguascalientes, Aguascalientes, Mexico. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.